UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Paradigm shift in the treatment options of hepatocellular carcinoma

Liver international, 2022-08, Vol.42 (9), p.2067-2079

2022

Volltextzugriff (PDF)

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori : a multicentre, open-label, randomised trial

The Lancet (British edition), 2013, Vol.381 (9862), p.205-213

2013

Volltextzugriff (PDF)

Serial increase and high alpha‐fetoprotein levels predict the development of hepatocellular carcinoma in 6 months

Hepatology research, 2023-10, Vol.53 (10), p.1021-1030

2023

Volltextzugriff (PDF)

Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?

Journal of the Formosan Medical Association, 2020-01, Vol.119 (1), p.3-11

2020

Volltextzugriff (PDF)

Systemic therapy for hepatocellular carcinoma: New agents and therapeutic hierarchy

Journal of the Formosan Medical Association, 2022-02, Vol.121 (2), p.451-453

2022

Volltextzugriff (PDF)

Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B

Hepatology international, 2023-10, Vol.17 (5), p.1139-1149

2023

Volltextzugriff (PDF)

Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial

Clinical infectious diseases, 2008-11, Vol.47 (10), p.1260-1269

2008

Volltextzugriff (PDF)

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B

Hepatology international, 2020-12, Vol.14 (6), p.997-1008

2020

Volltextzugriff (PDF)

Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy

Journal of the Formosan Medical Association, 2024-08, Vol.123 (8), p.891-898

2024

Volltextzugriff (PDF)

Effects of transjugular intrahepatic portosystemic shunt on abdominal muscle mass in patients with decompensated cirrhosis

Journal of the Formosan Medical Association, 2023-08, Vol.122 (8), p.747-756

2023

Volltextzugriff (PDF)

Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C

Journal of the Formosan Medical Association, 2021-03, Vol.120 (3), p.956-964

2021

Volltextzugriff (PDF)

Direct comparison of biopsy techniques for hepatic malignancies

Clinical and Molecular Hepatology, 2021, 27(2), , pp.305-312

2021

Volltextzugriff (PDF)

Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy

JGH open, 2021-08, Vol.5 (8), p.929-940

2021

Volltextzugriff (PDF)

High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments

PloS one, 2017-01, Vol.12 (1), p.e0170028-e0170028

2017

Volltextzugriff (PDF)

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy

Proceedings of the National Academy of Sciences - PNAS, 2011-03, Vol.108 (9), p.3719-3724

2011

Volltextzugriff (PDF)

Diversity and composition of gut microbiota in healthy individuals and patients at different stages of hepatitis B virus-related liver disease

Gut pathogens, 2023-05, Vol.15 (1), p.24-24, Article 24

2023

Volltextzugriff (PDF)

Letter to the Editor: Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men

Hepatology (Baltimore, Md.), 2023-11, Vol.78 (5), p.E97-E97

2023

Volltextzugriff (PDF)

Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C

Journal of the Formosan Medical Association, 2019-08, Vol.118 (8), p.1187-1192

2019

Volltextzugriff (PDF)

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan

Viruses, 2021-11, Vol.13 (11), p.2294

2021

Volltextzugriff (PDF)

Acoustic Radiation Force and Elasticity Imaging

Journal of medical ultrasound, 2016-03, Vol.24 (1), p.1-2

Hsu, Shih-Jer

2016

Volltextzugriff (PDF)

Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions

Journal of medical ultrasound, 2019-04, Vol.27 (2), p.81-85

2019

Volltextzugriff (PDF)

Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients

Journal of the Formosan Medical Association, 2020-03, Vol.119 (3), p.712-719

2020

Volltextzugriff (PDF)

Optimizing Survival Benefit by Surgical Resection by the Seven-Eleven Criteria in Barcelona Clinic Liver Cancer Stage A/B Hepatocellular Carcinoma beyond the Milan Criteria

Liver cancer (Basel ), 2023-12, Vol.12 (6), p.539-549

2023

Volltextzugriff (PDF)

Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions

Journal of the Formosan Medical Association, 2019-02, Vol.118 (2), p.556-564

2019

Volltextzugriff (PDF)

Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients

PloS one, 2015-09, Vol.10 (9), p.e0137852-e0137852

2015

Volltextzugriff (PDF)

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(70)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(50)
Life Sciences & Biomedicine
(43)
Humans
(31)
Male
(26)
Female
(24)
Middle Aged
(22)
Gastroenterology & Hepatology
(18)
Adult
(16)
Antiviral Agents - Therapeutic Use
(16)
Hepatitis C, Chronic - Drug Therapy
(15)
Hepatitis C
(13)
Aged
(12)
General & Internal Medicine
(11)
Genotype
(11)
Liver Cancer
(11)
Medicine, General & Internal
(11)
Taiwan
(11)
Drug Therapy, Combination
(10)
Hepatitis
(10)
Hepatitis C Virus
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Paradigm shift in the treatment options of hepatocellular carcinoma

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori : a multicentre, open-label, randomised trial

Serial increase and high alpha‐fetoprotein levels predict the development of hepatocellular carcinoma in 6 months

Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?

Systemic therapy for hepatocellular carcinoma: New agents and therapeutic hierarchy

Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B

Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B

Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy

Effects of transjugular intrahepatic portosystemic shunt on abdominal muscle mass in patients with decompensated cirrhosis

Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C

Direct comparison of biopsy techniques for hepatic malignancies

Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy

High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy

Diversity and composition of gut microbiota in healthy individuals and patients at different stages of hepatitis B virus-related liver disease

Letter to the Editor: Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men

Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan

Acoustic Radiation Force and Elasticity Imaging

Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions

Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients

Optimizing Survival Benefit by Surgical Resection by the Seven-Eleven Criteria in Barcelona Clinic Liver Cancer Stage A/B Hepatocellular Carcinoma beyond the Milan Criteria

Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions

Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients

Suchergebnisse filtern